Expands Osmolality Testing and Certification Program
Become OsmoLab Certified The Osmolality Lab offers the OsmoLab Certified mark to products that meet The Osmolality Lab Certification Program?s strict testing and evaluation criteria
CHARLOTTE, N.C., September 28, 2023 (Newswire.com)
-
The Osmolality Lab, with an established testing lab in Draper, Utah, and corporate offices in Star Valley, Wyoming, is expanding their capacity and East Coast reach with a new osmolality testing facility located in Kannapolis, North Carolina, just outside of Charlotte and about two hours west of the city of Raleigh and its well-established “Research Triangle Park”.
The Osmolality Lab’s new testing facility will be housed at the North Carolina Research Campus, a 350-acre collaborative research center in Kannapolis, NC, which currently features several commercial biotech operations, as well as dedicated human health, diet and exercise research groups from numerous North Carolina Universities, including NCSU, Appalachian State University, UNC Chapel Hill & UNC Charlotte. The expansion brings greater capacity for testing at The Osmolality Lab while establishing a physical presence for East Coast clients for greater service opportunities. This new testing lab will join the larger effort of helping establish the Raleigh-Charlotte area as North Carolina’s Innovation Corridor for scientific research.
The Osmolality Lab, the global leader in osmolality product testing, was founded in 2018 with the mission “to improve health and safety for all consumers by providing unique services to partners driven to create excellence in their category”. Their team tests and certifies in a variety of industries such as hydration beverages, functional beverages, spring waters, and personal lubricants, skin care, and more to help clients and consumers learn more about how the product performs so they can purchase with confidence. Products that meet The Osmolality Lab Certification Program’s strict testing and evaluation criteria can also be awarded the “OsmoLab℠ Certified” Mark to help communicate the commitment to transparency and product quality to consumers.
The Kosmos ultrasound system now offers the most advanced feature set of any hand-carried device compatible with Apple iOS
KOSMOS on iOS System in use for imaging. Tablet compatibility means ease of implementation, which, in turn, improves care
REDMOND, Wash., September 28, 2023 (Newswire.com)
-
EchoNous, a leader in transformative handheld point-of-care ultrasound solutions, is excited to announce a new advancement in its medical imaging technology. The acclaimed Kosmos system, known for its high-quality ultrasound performance and cutting-edge AI solutions, now provides advanced capabilities on compatible iOS tablets, empowering healthcare providers with increased accessibility and versatility.
With this latest development, EchoNous takes another major step forward in revolutionizing point-of-care ultrasound by increasing access to its platform across multiple operating systems. Integrating the Kosmos system with compatible iOS tablets allows clinicians to harness the power of advanced medical imaging on some of the highest-performance tablets available.
The Kosmos system is now available on three platforms, our own proprietary tablet as well as Android and iOS compatible tablets, offering the user flexibility to customize the system to suit their own preferences and clinical settings.
"Our commitment to improving patient care by driving innovation and our refusal to compromise on quality has led us to this remarkable milestone," said Graham Cox, CEO of EchoNous. "By expanding the Kosmos system's capabilities to compatible iOS tablets, we aim to empower clinicians with greater flexibility and efficiency, thereby enhancing their ability to make critical decisions for their patients."
The Kosmos system on iOS tablets maintains the same level of ultrasound performance and advanced AI technology for which EchoNous is well known. Some of the top features of the Kosmos iOS application include:
High-end 2D Imaging
M-Mode
Color Doppler Imaging (CDI)
Color Power Doppler (CPD)
Pulsed Wave (PW) Doppler for both Lexsa (Linear) and Torso (Phased Array) probes
Continuous Wave (CW) Doppler
Tissue Doppler Imaging (TDI)
Trio AI (Cardiac: Auto Guidance, Auto-Grading, Auto-Labeling)
AI FAST (Abdominal: Auto-Labeling)
Auto-Ejection Fraction (EF) calculation
Auto-VTI Tracing
DICOM SR for cardiac calculation
Cardiac Calcs
Vascular Calcs
Post Exam Processing
Launching the Kosmos system on compatible iOS tablets is a testament to EchoNous’ dedication to driving progress in point-of-care ultrasound. As EchoNous continues to lead the charge in AI-driven ultrasound, the company is empowering clinicians worldwide by continuously adding more capabilities and making its offerings even more capable and easier to use.
About EchoNous
Headquartered in Redmond, Washington, EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. For more information, visit www.echonous.com.
NEW YORK, September 28, 2023 (Newswire.com)
-
How much money is needed to retire comfortably? That is a very good question. It is also one for which there is no easy answer. The good news is resources like the free Yieldstreet retirement calculator can help find an answer that best fits each person’s circumstance, as well as the lifestyle they want to enjoy in retirement.
How Much Money Will Be Needed?
A basic rule of thumb for making this determination is guided by what is known as the 25x rule. Essentially, it states that in order to live without generating new income, a person will need to have accrued 25 times the amount of money they anticipate needing in retirement.
To arrive at this figure, one first multiplies their current monthly budget by 12 to define their annual budget. Multiplying the product of that calculation by 25 returns the amount needed—assuming all expenses remain constant.
At What Age Is Retirement Feasible?
The key is to calculate the total amount of time required to accrue the sum indicated by the application of the 25x rule. Subtracting the amount of savings currently on hand from the 25x result will indicate the additional amount needed.
Applying a compound interest calculator to that figure, assuming an annual growth rate of 6%, will indicate the amount by which the current savings will have grown at a given age.
Subtracting that number from the result of the 25x rule calculation—then dividing the difference by an estimated savings amount—will return the number of years required to reach the established monetary goal for each age chosen.
What is the Optimal Withdrawal Amount?
People who have considerable experience in these matters recommend adherence to the 4% rule. This calls for withdrawing 4% of retirement savings the first year, then repeating the process each following year, with an adjustment for rate of inflation.
Assuming a 6% average rate of return on investments with a 50/50 mix of stocks and bonds, withdrawals in these amounts can be sustainable for approximately 30 years.
This assumes the underlying portfolio remains invested during retirement—and the market returns historical averages. To counter the implied risk, alternative investments have the potential to make portfolios less sensitive to public market short-term swings.
Alternative Investments and Portfolio Diversification
Real estate, private equity, venture capital, digital assets, precious metals and collectibles are among the asset classes deemed alternative investments. These asset classes were traditionally accessible only to accredited investors and institutions buying in at very high minimums. However, Yieldstreet has opened a number of carefully curated alternative investment strategies to all investors.
These three calculations can help you plan for retirement. However, there are other elements to consider. These include factors such as taxes, inflation and required minimum distributions. The free Yieldstreet Retirement calculator also takes those into consideration to help arrive at a more accurate estimate.
IFC Films will be giving the horror film Stopmotion a theatrical release before it heads to the Shudder streaming service
Aisling Franciosi of The Nightingale andThe Last Voyage of the Demeter stars in the upcoming horror film Stopmotion, which is set to have its world premiere at Fantastic Fest, running in Austin, Texas from September 21st through the 28th. Ahead of the premiere screening, Variety reports that IFC Films has acquired North American and select International distribution rights to the film. They’re planning to give Stopmotion a theatrical release sometime in 2024, then it will head over to the Shudder streaming service.
Franciosi takes on the role of Ella Blake, a stop-motion animator who is struggling to control her demons after the loss of her overbearing mother. Suddenly alone in the world, she creates a macabre new puppet film, while struggling to maintain her sanity. As Ella’s mind starts to fracture, the characters in her animated film take on a terrifying life of their own, and the unleashed power of her imagination threatens to destroy her.
IFC Films and Shudder are both owned by AMC, and AMC Networks’ Scott Shooman had this to say about the distribution deal: “IFC and Shudder are ecstatic to bring Robert Morgan’s riveting live-action/animation hybrid to audiences everywhere. Stopmotion is excellent as it weaves together a unique, psychological-horror with unbelievable visuals. The film joins the ranks of critically acclaimed titles such as Mad God and The Wolf House – breaking ground for how we perceive stop-motion in horror. We are thrilled to distribute Robert Morgan’s first full-length feature for its theatrical release and presence on our streaming platform, Shudder.“
As Shooman mentioned, this is the feature debut of director Robert Morgan, who also wrote the screenplay with Robin King. Morgan has directed multiple short films over the last thirty years, including the “D is for Deloused” segment from the anthology film ABCs of Death 2.
Morgan provided the following statement: “IFC’s superb back catalogue speaks for itself, and Shudder’s embracing of the weirder and distinctive side of horror cinema means this is the perfect home for my first feature. I’m thrilled to be teaming up with them, and I’m excited to share Stopmotion with audiences very soon.“
Stopmotion was produced by Alain de la Mata and Christopher Granier-Deferre of BlueLight.
Any horror movie about living puppets has my attention, so I look forward to checking out Stopmotion. How does this one sound to you? Let us know by leaving a comment below.
With Expend4bles now playing in theaters, let us know what you thought of the latest installment of Sylvester Stallone’s action franchise.
The boys are back in action! It’s been nearly a decade since the release of the last film in Sylvester Stallone’s action franchise, but Expend4bles has finally arrived. The long-awaited action sequel took in $750,000 in previews on Thursday, with the film looking to open with around $15 million.
The Expend4bles cast features a mix of familiar faces, with Sylvester Stallone, Jason Statham, Dolph Lundgren, and Randy Couture all returning, as well as a few newbies, including Megan Fox, Curtis “50 Cent” Jackson, Tony Jaa, Iko Uwais, Jacob Scipio, Levy Tran, and Andy Garcia. “Armed with every weapon they can get their hands on and the skills to use them, The Expendables are the world’s last line of defense and the team that gets called when all other options are off the table,” reads the official synopsis. “But new team members with new styles and tactics are going to give ‘new blood’ a whole new meaning.” The film was directed by Scott Waugh from a screenplay by Kurt Wimmer, Tad Daggerhart, and Max Adams.
We’ve known that Sylvester Stallone would be exiting the franchise after this movie, but it seems his role is more limited than fans would have liked for his final appearance. “It’s primarily a spin-off entry for Jason Statham’s Lee Christmas, with the titular Expendables only supporting our hero on a personal mission, with Sylvester Stallone’s Barney Ross contributing little more than a cameo,” wrote our own Chris Bumbray in his review. “While that’s undeniably disappointing, Expend4bles is still a fun enough action flick if you keep your expectations in check. The budget seems much smaller than it was for the previous films, with abysmal CGI.” You can check out the rest of Bumbray’s review right here.
Expend4bles is now playing in theaters and is currently sitting at 17% on Rotten Tomatoes, placing it well behind The Expendables with 41%, The Expendables 2 with 67%, and The Expendables 3 with 31%. Let us know what you thought of Expend4bles in the comments below and where you’d rank it in the franchise!
Trailer: Vampire Queen Tara Reid takes on a team of vampire hunters led by Costas Mandylor in the Halloween release Bloodthirst
More than three years have passed since an IndieGogo campaign succeeded in raising funds for the vampire movie Bloodthirst, starring Tara Reid (Urban Legend). That project has since made its way through production, and now it’s ready to be set loose into the world. Bloodthirst is set to receive a digital and VOD release on October 31st, and you can check out the trailer in the embed above!
Directed by Michael Su from a screenplay written by Massimiliano Cerchi and Adrian Milnes, the film has the following synopsis: After the apocalypse, only two tribes remain: desperate humans and the roving vampires that feed on them. Across the desolate West, John Shepard seeks the aging head vampire, hoping to destroy him and free mankind. But when Shepard and his posse of native sons and farmer’s daughters joins forces with a local militia, they learn that they’re closer to the Master than they think…
John Shepard is played by Costas Mandylor (multiple Saw sequels), while Reid takes on the role of a vampire queen. Also in the cast are Robert LaSardo (Nip/Tuck), Bishop Stevens (Girl on the Third Floor), Johnny Huang (Attack of the Unknown), Sarah French (That’s a Wrap), Elissa Dowling (The Most Dangerous Game), Denny Nolan (Night of the Tommyknockers), Rich R. Rendon (Bridge of the Doomed), William ‘Bill’ Connor (The House That Eats Flesh), Ben Stobber (Apache Junction), Dee Cutrone (Death Count), Lance Caver (American Trash), Kevin Hager (Bermuda Island), Tatiana Sokolova (Killer Waves), and Eileen Dietz (The Exorcist).
Bloodthirst was produced by Michael Mahal and Sonny Mahal, with a whole army of people earning executive producer credits. The film has been rated R for bloody violence and language.
What did you think of the Bloodthirst trailer? Will you be watching this movie on Halloween? Let us know by leaving a comment below.
Bloodthirst looks like it could provide some low budget entertainment and I’m a fan of several of the actors in the cast. So I’ll be watching this one, as I’m on board to check out any movie that features a vampire queen Tara Reid taking on vampire hunters who are armed with garlic shotgun shells.
LAS VEGAS, September 27, 2023 (Newswire.com)
-
Advanced Radiotherapy Technologies (“ART Health”), a Kingsbarn company, has started construction of a state-of-the-art radiation treatment center in Henderson. The center is expected to open for patient care during the first half of 2024 and will have the capacity to treat thousands of cancer patients annually.
The new facility will include leading-edge cancer therapies not yet offered in the area, such as Biology-guided Radiation Therapy (BgRT) using RefleXion Medical’s SCINTIX treatment system. SCINTIX therapy is the only radiotherapy treatment delivery modality to leverage radiotracers for live tumor targeting. This new use of radiotracers turns tumors into biological beacons that actively control treatment delivery in real time via a continuous stream of data. SCINTIX is unique in that it can treat multiple tumors at a time. The center will also include Varian Medical’s Edge Radiosurgical system, Siemen’s PET/CT, nuclear medicine, and brachytherapy. This will be the most advanced radiation treatment center in Nevada, providing the residents of metropolitan Las Vegas and Southern Nevada access to the most contemporary cancer therapies.
For those diagnosed with cancer, accessing the latest technology and the most effective therapies to ensure the best treatment outcomes is often a challenge. Many times, the equipment to provide those treatments is cost-prohibitive at the local level, requiring the patient to travel to major hospitals or university medical centers. ART Health’s goal is to provide leading-edge cancer treatment at the community level so that patients receive the best possible outcomes close to their homes and family support systems.
Including the center in Las Vegas, ART Health has begun the development of three radiation treatment centers with world-class clinical partners, including a prominent local radiation oncology practice, a large regional healthcare system and a major medical academic institution. ART Health will continue to identify clinical partners and new center locations as it continues its expansion nationwide.
“We are very pleased to bring this state-of-the-art radiation treatment center to Las Vegas Valley,” stated Jeff Pori, CEO of Kingsbarn, when discussing ART Health’s new Henderson clinic. “There are very few major cancer centers that offer these next-generation modalities for cancer management, and we are proud to bring these cutting-edge technologies to our own hometown. We are confident that the combination of these new radiation technologies and world-class physicians will significantly elevate and advance the way we treat cancer patients in southern Nevada.”
Amazon will be adding commercials to Prime Video next year, but you’ll have to pay a few extra bucks to remove them.
Buckle up, Amazon is getting ready to introduce commercials to Prime Video.
Starting early next year, commercials will appear in movies and TV series streaming on Prime Video in the U.S., UK, Germany, and Canada. France, Italy, Spain, Mexico, and Australia will follow suit later in the year. Prime members currently pay $14.99 for the service, which includes free shipping on Amazon and other benefits, but if they want to avoid commercials moving forward, they will have to pay an additional $2.99 per month in the U.S.
It’s not clear how many commercials we’re talking about, but Amazon said that they will be “limited,” with their goal being “to have meaningfully fewer ads than linear TV and other streaming TV providers.” Almost all major streaming services include ad-supported subscriptions in addition to ad-free, including Netflix and Disney+, so Prime Video is simply the latest to join up. This change “will allow the company to continue investing in content and increasing that investment over time.” Got to pay for The Lord of the Rings: The Rings of Power somehow.
Does it feel like we’re going backwards? When streaming started growing in popularity, one of the main draws was getting away from the commercials. But little by little, streaming services realized they really missed that sweet, sweet advertiser money. I can’t say I blame them, but with most of us paying for multiple streaming services in order to have all our favourites in one place, have we just come full circle back to television?
If you’re already a Prime Video subscriber, are you willing to cough up a few extra bucks to avoid commercials next year?
TAMPA, Fla., September 27, 2023 (Newswire.com)
-
The Brewing Funds the Cure initiative allows the passion and creativity of the brewing industry to help fund critical research in collaboration with the National Pediatric Cancer Foundation. The signature program for Brewing Funds the Cure is the annual release of Rising Hope. Now in its 5th year, the program's goal is to have one brewery in each state produce the iconic “Rising Hope” brew. With the 2023 release of Rising Hope, craft brewing partners across the country have raised over $1 million for pediatric cancer research!
Brew masters from Florida Avenue Brewing and Mike Hess Brewing have designed an East Coast (Hazy Mango IPA) and West Coast (Orange Blossom Pale Ale) recipe for breweries to choose from. Partners Country Malt Group, Yakima Chief Hops, Amoretti Fruit Puree and AB Biotech provide free ingredients to each of the Rising Hope breweries. In addition, Blue Label Packaging Co has donated labels for canning, and Taphandles are providing signature tap handles for all breweries. The signature brew will be a limited release, and 100% of the proceeds will benefit the National Pediatric Cancer Foundation. 2023 partners will be updated on the virtual map at: www.brewingfundsthecure.org.
Why is this important?
Cancer is the #1 cause of death by disease among children
43 children per day are expected to be diagnosed with cancer
Only 4% of the billions of dollars that are spent annually on cancer research and treatments are directed toward treating childhood cancer
• More than 95% of those who survive childhood cancer will have a significant health-related issue by the time they are 45 as a result of being treated with drugs designed for adults.
How to Get Involved with Brewing Funds The Cure
Join/Donate:
Organizations can join Brewing Funds the Cure by going to the NPCF’s Brewing Funds the Cure website. To inquire about partnering or to donate: www.brewingfundsthecure.org
Support in style! Individuals can donate $43 or more and receive a one-time gift of Brewing Funds the Cure Hat & sticker. https://give.nationalpcf.org/give/492466/#!/donation/checkout
Date:
Rising Hope will begin to release in September 2023 and will be available until it runs out. For specific release information, please follow social media channels for the specific partner brewery in your area. A full list of participating breweries can be found at www.brewingfundsthecure.org
Get Social:
Follow @brewingfundsthecure on Instagram! Tag us, message us, and use #brewingfundsthecure to get involved and help promote BFTC.
The National Pediatric Cancer Foundation is a non-profit organization based in Tampa, FL. Founded in 1991, we have raised upwards of $35 million and partner with over 30 hospitals nationwide. 89 cents of every dollar raised funds research and new medical trials to find less toxic, more therapeutic solutions for childhood cancer. We are proud of our dedication to fiscal responsibility, receiving the highest rating 11 years in a row from Charity Navigator, putting us in the top 2% of all charities nationwide. For more information, visit www.NationalPCF.org or connect via Facebook, Twitter or Instagram.
The multi-study, patented ingredient delivers experiential benefits for cognitive performance.
SADDLE BROOK, N.J., September 27, 2023 (Newswire.com)
-
Nutrition21 LLC (“Nutrition21”) an Everwell Health Company, and a leader in clinically-studied branded ingredients, announced today the launch of its nootropic ingredient nooLVL® into the cognitive health space. The unique patented complex of nooLVL is non-stimulant and provides multiple cognitive benefits, including focus, concentration, improved memory, and energy.
The results of nooLVL in two double-blind, placebo-controlled clinical studies(1,2) conducted with healthy adults in the United States demonstrated:
Improved cognitive function even under high mental and cognitive demands
Improvements in visual attention and information processing
Enhanced accuracy
Fast action – working in just 15 minutes, as a non-stimulant to enhance energy
The Bonded Arginine Silicate in nooLVL is a highly bioavailable, long-lasting form of arginine that increases nitric oxide production and blood flow. The increase in nitric oxide supports the delivery of oxygen and essential nutrients to the brain. This method of action delivers focus you can feel without the potential downsides commonly associated with other cognitive health ingredients or stimulants.
With a neutral taste profile, nooLVL is ideal for powders and stick packs and can be formulated into foods and beverages. The R&D Team at Nutrition21 also offers added value by assisting customers with formulation expertise to help fast-track product development projects.
The cognitive health market continues to grow and includes mental health, mood, and stress as well as enhanced memory, focus, and energy. Nutrition Business Journal (NBJ) estimates that sales of brain health supplements in the United States hit $1.2 billion last year—an 8.1% increase over 2021.
“The market has been asking for a non-stimulant solution that really works, and Nutrition21 has developed it. While the Nutrition21 Team originally developed nooLVL as the groundbreaking functional ingredient for the high cognitive demands of the e-sports market, it became apparent that a much wider consumer market could benefit by using it. Everyone ranging from students to parents, professionals, and athletes can benefit from using nooLVL,” said Joe Weiss, President, Nutrition21.
Study Citations
1. Effects of Inositol-Enhanced Bonded Arginine Silicate Ingestion on Cognitive and Executive Function in Gamers. Nutrients, 13(11), 3758. https://doi.org/10.3390/nu13113758
2. A Prospective Study Evaluating the Effects of a Nutritional Supplement Intervention on Cognition, Mood States, and Mental Performance in Video Gamers. Nutrients, 11(10). https://doi.org/10.3390/nu11102326
About nooLVL®
The Bonded Arginine Silicate in nooLVL is a highly bioavailable, long-lasting form of arginine that increases nitric oxide production and blood flow. The increase in nitric oxide supports the delivery of oxygen and essential nutrients to the brain. The unique patented complex of nooLVL is non-stimulant and provides multiple cognitive benefits, including focus, concentration, improved memory, and energy.
About Nutrition21, LLC
Nutrition21, an Everwell Health company, is an industry-leading developer and marketer of efficacious, high-value, clinically substantiated ingredients for use in dietary supplements, functional foods and beverages. With decades of experience, the company’s scientific platform has continued to create unique, patented products that are both safe and clinically effective. To build consumer trust, Nutrition21 ensures product efficacy and safety through a product development process that involves rigorous preclinical and clinical research. The company currently holds more than 50 domestic and international issued and pending patents for its ingredients which support unique claims associated with sports nutrition, weight management, cognitive health, and beauty-from-within, among others.
Everwell Health aims to help people look, feel and perform their best by advancing the science of safe, convenient, and attainable functional ingredients. Everwell Health enables our partners to win by providing trusted ingredient solutions that help all to look, feel and perform their best. The company adds meaningful value to dietary supplement, food and beverage brands by offering scientifically substantiated functional ingredient solutions. The company is actively focused on business development partnerships across the functional ingredients market.